We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
- Authors
Cortes, Jorge E; Kantarjian, Hagop M; Goldberg, Stuart L; Powell, Bayard L; Giles, Francis J; Wetzler, Meir; Akard, Luke; Burke, John M; Kerr, Robert; Saleh, Mansoor; Salvado, August; McDougall, Karen; Albitar, Maher; Radich, Jerald; Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group
- Abstract
Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 28, p4754
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.20.3869